Drieda Zace

Jan 11, 2025 | sti.bmj.com | Drieda Zace |Marina Daskalopoulou |Rachel Herbert |Giovanni Villa

Viral suppression (VS) following initiation of long-acting cabotegravir/rilpivirine (LA-CAB/RPV) among people with HIV, adherence challenges and baseline viraemiaThe Ward 86 publicly funded San Francisco HIV clinic serves people experiencing socioeconomic, psychological and adherence challenges. This study examined the persistence of LA-CAB/RPV and durability of VS (HIV RNA <50 c/mL) at 48 weeks among 59 participants (53% unstable housing, 63% substance use and 49% CD4 <200 cells/mm3).

May 31, 2024 | sti.bmj.com | Drieda Zace |Marina Daskalopoulou |Weiming Tang

Strategies for evaluating penicillin allergy in STI servicesOver-reporting of penicillin or beta-lactam allergy often complicates STI management.

Jan 17, 2024 | sti.bmj.com | Giovanni Villa |Drieda Zace |Sonia F Raffe

Pay-it-forward incentives as a strategy to increase hepatitis B and C testing in the communityPay-it-forward incentives involve offering a free test and then giving a chance to donate money to support testing of another anonymous person.

Aug 21, 2023 | sti.bmj.com | Nadja A. Vielot |Drieda Zace |Tor Vergata

Cervical screening intervals can be extended in women living with HIV following an initial negative human papillomavirus DNA testFirmer evidence is needed to guide cervical cancer screening in women with HIV. A study from India enrolled women with no history of cervical intraepithelial neoplasia (CIN) or cancer and with normal colposcopy at baseline. Participants underwent annual colposcopies followed by three yearly human papillomavirus (HPV) DNA testing.

Aug 17, 2023 | sti.bmj.com | Nadja A. Vielot |Drieda Zace |Tor Vergata

Cervical screening intervals can be extended in women living with HIV following an initial negative human papillomavirus DNA testFirmer evidence is needed to guide cervical cancer screening in women with HIV. A study from India enrolled women with no history of cervical intraepithelial neoplasia (CIN) or cancer and with normal colposcopy at baseline. Participants underwent annual colposcopies followed by three yearly human papillomavirus (HPV) DNA testing.